Vera Therapeutics Inc (VERA)
41.38
-0.56
(-1.34%)
USD |
NASDAQ |
May 17, 16:00
41.38
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Cash from Financing (TTM): 302.10M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 302.10M |
December 31, 2023 | 133.54M |
September 30, 2023 | 129.42M |
June 30, 2023 | 130.03M |
March 31, 2023 | 129.65M |
December 31, 2022 | 101.93M |
September 30, 2022 | 86.14M |
Date | Value |
---|---|
June 30, 2022 | 85.24M |
March 31, 2022 | 134.18M |
December 31, 2021 | 53.88M |
September 30, 2021 | 128.76M |
June 30, 2021 | 128.67M |
March 31, 2021 | 80.30M |
December 31, 2020 | 85.29M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
53.88M
Minimum
Dec 2021
302.10M
Maximum
Mar 2024
122.08M
Average
128.72M
Median
Cash from Financing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -625.00M |
Alpine Immune Sciences Inc | 185.56M |
Fate Therapeutics Inc | 95.37M |
Mersana Therapeutics Inc | 78.96M |
Equillium Inc | -7.799M |